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Abstract
Aside fromwell-characterized immune-mediated ataxias with a clear trigger and/or association with specific neuronal antibodies,
a large number of idiopathic ataxias are suspected to be immune mediated but remain undiagnosed due to lack of diagnostic
biomarkers. Primary autoimmune cerebellar ataxia (PACA) is the term used to describe this later group. An International Task
Force comprising experts in the field of immune ataxias was commissioned by the Society for Research on the Cerebellum and
Ataxias (SRCA) in order to devise diagnostic criteria aiming to improve the diagnosis of PACA. The proposed diagnostic criteria
for PACA are based on clinical (mode of onset, pattern of cerebellar involvement, presence of other autoimmune diseases),
imaging findings (MRI and if available MR spectroscopy showing preferential, but not exclusive involvement of vermis) and
laboratory investigations (CSF pleocytosis and/or CSF-restricted IgG oligoclonal bands) parameters. The aim is to enable
clinicians to consider PACA when encountering a patient with progressive ataxia and no other diagnosis given that such
consideration might have important therapeutic implications.
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Introduction
Immune-mediated cerebellar ataxias (IMCA) include ataxias
where the trigger is known, e.g. paraneoplastic cerebellar degen-
eration (PCD) [1], gluten ataxia (GA) [2], post-infectious
cerebellitis (PIC) [3] as well as ataxias where neuronal antibodies
have been convincingly shown to be directly involved in the
pathogenesis of the ataxia. The term primary autoimmune cere-
bellar ataxia (PACA) was introduced to describe a group of pa-
tients with suspected IMCA in which neither a trigger nor any
pathogenic neuronal antibodies have been discovered as yet [4].
A task force comprising clinicians with an interest and
extensive clinical experience in the management of IMCA
was formed in 2017 at the request of the Society for
Research on the Cerebellum and Ataxias (SRCA). The aim
of this international task force was to use their clinical exper-
tise in devising consensus diagnostic criteria in an attempt to
assist clinicians to suspect PACA as a potential diagnosis
amongst patients with otherwise idiopathic sporadic ataxia.
This is a very critical step enabling the consideration of early
therapy aiming to preserve or restore cerebellar reserve.
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Primary Autoimmune Cerebellar Ataxia
(PACA)
The task force proposes that the term primary autoimmune
cerebellar ataxia (PACA) should encompass all ataxias that
fulfil the criteria outlined in Fig. 1 with the following clarifi-
cations: PACA can be associated with neuronal antibodies.
However, the term PACA should not be used if such neuronal
antibodies have already been shown to be directly involved in
the pathogenesis of the ataxia (e.g. DPPX, mGluR1,
GABABR, anti-GAD) or are markers of ataxias with a known
trigger (e.g. anti-Yo in PCD or antigliadin antibodies in GA).
The task force recognizes the possibility of future clarification
of antibody pathogenicity in patients that currently meet the
criteria for PACA. In the event of such discovery, the ataxia in
question would no longer come under the umbrella of PACA
but would bear the name of the specific pathogenic antibody
(e.g. DPPX ataxia). The task force acknowledges that ataxias
are designated as PACA (as per criteria below) although all
immune mediated will ultimately prove heterogeneous, in
terms of both pathogenesis and optimum treatment.
However, the consideration and recognition of PACA should
alert the clinician to the possibility of a potentially treatable
ataxia which is the primary aim of this work.
Clinical Pointers to PACA
Most immune-mediated ataxias have a predilection for
vermian involvement although hemispheric involvement is
not common [5]. The clinical correlate is that of gait ataxia
either in isolation or more prominent than limb ataxia. This is
in contrast to most genetic and degenerative ataxias where the
cerebellar involvement is usually more global affecting both
vermis and hemispheres equally, resulting in both limb inco-
ordination, speech involvement as well as gait instability.
Fig. 1 MR spectroscopy of the
cerebellar vermis of a patient with
PACA before and a year after
treatment with mycophenolate.
Note the improvement of the
NAA/Cr area ratio from 0.92 pre-
treatment to 1.12 after treatment.
This was associated with clinical
improvement
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Genetic ataxias tend to progress slowly (usually over
many years) with often a poorly defined temporal onset
uncommon. Most IMCAs are of acute (days) or subacute
(weeks or months) onset. Progression as a rule is faster in
immune than in genetic ataxias, and immune ataxias follow
a progressive course when untreated. The only non-
immune-mediated ataxia where progression can be fast is
cerebellar variant of multiple system atrophy (MSA-C).
However a number of additional features should allow
the distinction of MSA-C from PACA. In MSA-C auto-
nomic dysfunction (urinary and postural symptoms, impo-
tence, vivid dreams, sleep apnoea), early speech involve-
ment, global ataxia, sometimes extrapyramidal features
and characteristic MR imaging appearances (usually later
on in the disease process) with atrophy of the pons and
“hot cross bun” sign and selective hypometabolism on
18-FDG PET are all common features [6]. Careful identi-
fication of these features helps the differential diagnosis of
MSA-C from IMCA.
It is extremely rare for an IMCA to be associated with a
family history of ataxia. Therefore, the presence of a family
history of ataxia suggests a genetic rather than an immune
ataxia. It is not uncommon, however, for either the patient
with immune ataxia or their first-degree relative being affected
by another autoimmune disease [7]. Indeed this observation
should alert to the possibility of PACA. Common examples of
such autoimmune diseases include thyroid autoimmunity,
Sjogren’s syndrome, pernicious anaemia, type 1 diabetes
mellitus (DM) and vitiligo.
Investigations Pointing to PACA
The presence of antibodies that suggest autoimmune tendency can
be helpful in the diagnosis of IMCA. Such antibodies are not
always pathogenic, may not necessarily be anti-neuronal but can
simply signify tendency to autoimmunity even in the absence of a
concurrent autoimmune disease (e.g. presence of thyroid peroxi-
dase, intrinsic factor antibodies, anti-Ro). There is an ever-
increasing number of anti-neuronal autoantibodies that have been
identified in the context of immune-mediated neurological dis-
eases, including ataxias [8] (see Table 1). Such anti-neuronal au-
toantibody tests are often not readily available even in regional
immunology laboratories. In addition these antibodies are not
necessarily pathogenic or well-characterized but still may provide
some indirect evidence for PACA.
Cerebrospinal fluid examination can sometimes provide
some pointers to an immune pathogenesis with the presence
of pleocytosis (anything above normal range for white cells)
and/or CSF-restricted IgG oligoclonal bands [9, 10].
MR imaging of the cerebellum may also provide further
support with evidence of preferential involvement of the ver-
mis (at least at the initial presentation) in the context of PACA.
In addition, if available MR spectroscopy of the vermis (mea-
suring N-acetyl aspartate to creatine, NAA/Cr ratio) can be a
very sensitive test of cerebellar dysfunction and a useful mon-
itoring tool particularly when considering immunosuppres-
sion (Fig. 1) [11, 12].
There is some emerging evidence to suggest that immune-
mediated ataxias are more likely to be linked to “brain hyperex-
citability” (e.g. DPPX ataxia, myoclonic ataxia due to refractory
coeliac disease) as indicated by cortical myoclonus (using back
averaging), giant somatosensory evoked potentials, abnormal
blink reflex and exaggerated startle responses [13, 14].
Immunohistochemistry using sera or CSF from patients
with suspected PACA often shows reactivity with cerebellar
tissue, which is not the case when using sera from patients
with genetic ataxias [7].
Accessibility to tissue for biopsy, such as, for example,
peripheral nerve in the context of any concurrent peripheral
neuropathy or skin in the presence of a vasculitic skin rash,
may also be helpful in alerting to the possibility of PACA.
Given that PACA, as proposed in this article, is a new entity
and that it is likely to prove to be heterogeneous, it is difficult
Table 1 Some examples of autoantibodies observed in primary autoimmune cerebellar ataxia
1 Examples of autoantibodies associated with non-neurological autoimmune diseases that may raise suspicion of PACA
Thyroid peroxidase, thyroglobulin PACA, thyroid autoimmune diseases
Anti-SSA (Ro), SSB (La) PACA, Sjogren’s syndrome
2 Examples of autoantibodies reported only in a few patients with ataxia, thus significance in the context of ataxia is less well characterized but their presence may
raise suspicion of PACA
Autoantibody Clinical features
Anti-Sj/ITPR-1 Variable clinical course
Anti-Ca/ARHGAP26 Variable clinical course. Association with neoplasm reported
Anti-MAG Chronic gait ataxia and neuropathy. Ataxia is central in origin
Anti-Septin-5 Chronic cerebellar syndrome, no improvement after immunotherapy
Anti-neurochondrin Chronic cerebellar/brainstem syndrome
Anti-Nb/AP3B2 Subacute cerebellar ataxia
Anti-Homer-3 Subacute cerebellar ataxia
ITPR1, inositol 1,4,5-triphosphate receptor type 1; ARHGAP26, Rho GTPase-activating protein 26; MAG, myelin-associated glycoprotein
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to put emphasis on any PM pathological findings based on
what is available in the literature. Furthermore, most of the
literature refers to well-characterized immune-mediated
ataxias such as PCD and GA [15, 16].
Diagnostic Criteria for PACA (Fig. 2)
The following criteria need to be fulfilled to be able to diag-
nose PACA:
1. Predominantly subacute or acute pure cerebellar syndrome
(gait ataxia that may be associated with variable degrees of
limb incoordination, dysarthria, nystagmus, diplopia)
2. MRI at presentation usually normal or may show primar-
ily cerebellar vermian atrophy with (if available) reduced
MR spectroscopy (NAA/Cr ratio) of the vermis
3. At least 2 of the following:
a. CSF pleocytosis and/or positive CSF-restricted IgG
oligoclonal bands
Fig. 2 Flow diagram showing the
diagnostic criteria for PACA in
the context of other immune-
mediated ataxias
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b. History of other autoimmune disorders or family his-
tory of autoimmune disorders in first-degree relatives
c. Presence of antibodies that support autoimmunity but
not yet shown to be either directly involved in ataxia
pathogenesis (Table 1) or to be markers of ataxia with
a known trigger
4. Exclusion of alternative causes made by an experienced
neurologist or ataxia specialist (including other causes of
immune ataxia such as PCD, GA, PIC and ones that are
associated with well-characterized pathogenic antibodies)
Discussion
This is the first attempt to devise consensus diagnostic criteria
for PACA by an international task force comprising experts in
the field of immune ataxias. The task was commissioned by
the Society for Research on the Cerebellum and Ataxias
(SRCA). The significant progress in the genetic characteriza-
tion of the ataxias has highlighted the fact that in a large
number of patients with idiopathic late onset ataxia and no
family history of ataxia (sporadic), the ataxia is unlikely to
be due to any known genetic defect or due to neurodegenera-
tion. A potential autoimmune pathogenesis should be consid-
ered for such patients.
In a recent prospective study, out of a total of 1500 patients
with progressive ataxia, IMCAs accounted for 26% [17]. In
the same series, idiopathic sporadic ataxias accounted for 20%
of all ataxias. It is amongst these 20% that PACA can be
potentially identified and hopefully diagnosed using the pro-
posed criteria.
It has been argued that a substantial number of this 20% of
patients with idiopathic sporadic ataxia still have a genetic
defect that accounts for their ataxia but has not as yet been
identified. Despite the rapid development in genetic testing,
including new generation sequencing, screening of 114 pa-
tients with sporadic idiopathic adult onset ataxia, attending
the Sheffield Ataxia Centre, using a panel containing 175
genes associated with ataxia, identified a genetic cause in just
6% (personal observation).
Degenerative causes of ataxia with a well-established path-
ological characterization currently only include MSA-C, an
entity that is clinically very distinct. There is no evidence of
a common neurodegenerative pathological mechanism that
would potentially characterize or account for some of the
20% of idiopathic sporadic ataxias. Within this group, it is
likely that a substantial number of patients have PACA.
Correctly diagnosing patients with PACA is of potential ther-
apeutic importance.
A retrospective study showed that amongst 118 patients
with suspected IMCA, 55 had non-paraneoplastic ataxia
[18]. The majority of these 55 patients had ataxia associated
with well-characterized neuronal antibodies (i.e. not PACA).
All 118 patients had received some form of immunotherapy,
and neurological improvement was reported in 54 patients
(46%). Regression analysis revealed that improvements were
significantly more common amongst patients with non-
paraneoplastic ataxias.
In conclusion, we present here for the first time the consen-
sus diagnostic criteria in an attempt to aid the diagnosis of
PACA. Our aim is to facilitate the diagnosis of PACA in order
to instigate appropriate immunotherapy, gather a large number
of cases into a registry and allow clinical trials. These criteria
will help elucidate the epidemiology and pathogenesis of
PACA. As with any criteria, they are subject to future im-
provements in order to refine and improve diagnosis.
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